Blood-age and genes together may flag dementia risk years earlier

A blood-based aging signal may sharpen dementia risk forecasts

A study led by researchers at King’s College London suggests that dementia risk may be estimated more precisely by combining two kinds of information that usually sit in separate buckets: genetic susceptibility and biological aging. The central finding is straightforward but potentially important for prevention. People whose biological age appears older than their chronological age were more likely to go on to develop dementia, and the risk rose further when that accelerated aging signal was paired with the highest inherited risk profile.

The work, published in

Alzheimer's & Dementia

, adds to a growing push to detect neurodegenerative disease before symptoms become obvious. Dementia is still most strongly tied to age, but age alone does not explain who develops the condition, when it begins, or why some people appear to decline earlier than others. The new analysis argues that biological aging, measured through blood-based clues, may help fill part of that gap.

What the researchers found

The study reported that having a biological age older than one’s actual age was linked to a greater likelihood of developing dementia, with a particularly strong association for vascular dementia. It was also associated with an earlier age of onset across dementia subtypes. In practical terms, that means the blood-derived aging measure was not simply tracking late-life frailty in general; it appeared to be connected to both whether dementia emerged and how early it did so.

The most striking result involved people at the top end of genetic risk. According to the researchers, participants who showed advanced biological aging and also carried two copies of the APOE ε4 allele were 10 times more likely to develop dementia. The study further suggested that genetic risk and biological aging largely act independently, pointing to distinct pathways that may converge on the same clinical outcome.

That independence matters. If biological aging captures processes that are at least partly modifiable, then it could give clinicians and researchers something actionable even when a person’s genes cannot be changed. Lead author Dr. Julian Mutz said the findings indicate biological aging data could help identify people at risk before clinical symptoms emerge and could support preventive strategies built around a simple blood test.

Why the result stands out

Dementia affects an estimated 982,000 people in the UK, and projections cited in the report suggest that figure could rise to 1.4 million by 2040. At the same time, researchers and public health officials increasingly argue that a substantial share of cases may be delayed or prevented by addressing modifiable risk factors. The appeal of the new study is that it tries to bridge those two realities: a disease strongly shaped by aging, but not wholly dictated by fate.

If validated in broader settings, the approach could help stratify patients for monitoring, lifestyle interventions, or future early-stage therapies. A blood test that captures biological aging would be less burdensome than many specialist neurological assessments and more scalable than imaging-heavy screening programs. It could also help researchers design prevention trials by identifying people who are at elevated risk but have not yet developed symptoms.

There are still clear limits. The source material does not describe the full testing pathway that would be required before such an approach could be used routinely in clinics, and risk estimation is not the same as diagnosis. A person with accelerated biological aging is not necessarily destined to develop dementia, just as someone without that signal is not guaranteed protection. The study instead points to a probabilistic tool that could improve how risk is understood.

A step toward earlier intervention

The broader importance of the work is its timing. Dementia care systems remain under pressure, while drug development and early intervention efforts depend on finding at-risk patients sooner. A practical screening layer that combines inherited risk with a dynamic measure of how the body is aging could become valuable precisely because it moves the conversation earlier, before memory loss and functional decline become obvious.

Professor Marian Knight of the UK’s National Institute for Health and Care Research infrastructure said earlier detection and treatment would benefit not only patients but also the families, friends, and medical staff supporting them. That framing captures why incremental advances in risk prediction can matter. Even without an immediate cure, better forecasting can change planning, clinical surveillance, and the design of prevention strategies.

For now, the study’s message is measured rather than transformative. Biological age appears to add meaningful information to dementia risk, especially when read alongside APOE status. The result does not solve dementia, but it does suggest a more refined way to identify vulnerability before symptoms take hold. In a field where timing is everything, that may prove to be one of the most useful advances of all.

This article is based on reporting by Medical Xpress. Read the original article.